Bank of America’s Puma Biotechnology PBYI Stock Holding History

Bank of America’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$215K	–	7314
2019 Q3	$215K	Sell	20,000 -38,700	-66%	-$418K	﹤0.01%	5627
2019 Q2	$746K	Sell	58,700 -89,900	-60%	-$2.07M	﹤0.01%	4784
2019 Q1	$5.76M	Buy	148,600 +35,800	+32%	+$1.09M	﹤0.01%	3029
2018 Q4	$2.29M	Sell	112,800 -2,100	-2%	-$63K	﹤0.01%	3727
2018 Q3	$5.27M	Buy	114,900 +30,000	+35%	+$1.45M	﹤0.01%	3130
2018 Q2	$5.02M	Buy	84,900 +33,300	+65%	+$1.93M	﹤0.01%	3149
2018 Q1	$3.51M	Sell	51,600 -4,000	-7%	-$300K	﹤0.01%	3409
2017 Q4	$5.5M	Sell	55,600 -13,400	-19%	-$1.5M	﹤0.01%	3035
2017 Q3	$8.26M	Buy	69,000 +31,500	+84%	+$2.93M	﹤0.01%	2704
2017 Q2	$3.28M	Buy	+37,500	New	+$2.1M	﹤0.01%	3439
2017 Q1	–	Sell	-15,000	Closed	-$461K	–	7168
2016 Q4	$461K	Hold	15,000	–	–	﹤0.01%	4853
2016 Q3	$1.01M	Buy	+15,000	New	+$758K	﹤0.01%	4161
2015 Q4	–	Sell	-7,500	Closed	-$565K	–	7416
2015 Q3	$565K	Hold	7,500	–	–	﹤0.01%	4722
2015 Q2	$876K	Buy	+7,500	New	+$1.36M	﹤0.01%	4214

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's PBYI Position: Q2 2026 in Review

Bank of America reduced its Puma Biotechnology (PBYI) stake by 21% in Q2 2026, selling an estimated $63.1K and leaving 31,747 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #5270.

Bank of America first reported a position in PBYI in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.1M in Q4 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Bank of America held 31,747 shares of Puma Biotechnology worth $257K as of Q2 2026.
Bank of America sold 8,617 Puma Biotechnology shares in Q2 2026, an estimated $63.1K.
Puma Biotechnology made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5270 holding.
Bank of America first reported a position in Puma Biotechnology in Q2 2013 and has held it in 53 quarters since.
Bank of America's Puma Biotechnology position peaked at $22.1M in Q4 2017.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.